Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120:

Size: px

Start display at page:

Download "Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120:"

서호 경
5 years ago
Views:

3 Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 03; 1:

4 Day Normal MLE Lotion Lotion MLE Cream Cream Day Normal MLE Lotion Lotion MLE Cream Cream

5 Day 4 Day 8 Day 1

6 (%) P-value= P-value= % P-value= % 23.63% 16.02% 48.30% 32.74% 0 Day 4 Day 8 Day 1 (%) 100 P-value= % % 7.41%.6% 61.22% 37.46% 0 Day 4 Day 8 Day 1

7 Treatment X Duration(wk) In children(aged between 6mo and 12y) MOM 0.1% cr od X3 HYDV 0.2% cr bid X3 MOM 0.1% cr od X 3 CLO 0.0% cr bid X 3 MOM 0.1% cr od X 6 HYD 1.0% cr bid X 6 No. of patients treated (evaluated) (30) 30(30) 24(23) 24(19) Treatment outcome decrease in total sign and symptom severity score(%) bid=twice daily; CLO=clobetasone; cr=cream; HYD=hydrocortisone; HYDV=hydrocortisone valerate; MOM=mometasone; od=once daily; p vs comparator < STUDY 1 > < STUDY 2 > Decrease in total sign and symptom score(%) MOM(n=109) FLU(n=109) MOM(n=66) TRI(n=66) < STUDY 1 > Fluocinolone acetonide 0.02% 1 < STUDY 2 > Triamcinolone acetonide 0.1% 1 **P<0.001 vs comparator Duration of treatment (days) Duration of treatment (days) Study design Treatment Duration (days) No. of subjects Effect on serum cortisol levels r, db, pg nb r, db r, nb MOM 0.1% ung od 1g/day HYDB 1.0% ung od 1g/day MOM 0.1% ung 10g/day(h/day) a MOM 0.1% ung 30g/day(22h/day) a MPA 0.1% ung 30g/day(22h/day) a MOM 0.1% cr 16g/day(11h/day) a HYDB 0.1% cr 16g/day(11h/day) a MOM HYDB No effect on serum cortisol levels MOM MPA MOM > HYDB a:application under airtight occlusion. cr=cream; db=double-blind; HYDB=hydrocortisone butyrate; MOM=mometasone; MPA=methylprednisolone aceponate; nb=nonblind; od=once daily; pg=parallel group; r=randomised; ung=ointment; indicates similar effect; > indicates significantly greater effect.

8 Lotion Cream Mometasone furoate Dermotasone Drug Information Ref.) 1) Drugs Jan; (1): ) Australas J Dermatol. 1991; 32(2): ) J Am Acad Dermatol Apr; 24(4): 3-7 4) Cutis 1988 Nov; 42(): 480-, 1996 Feb;7:13-18 ) N Z Med J May 26; 106(96): 3-6) J Int Med Res Nov-Dec; 18(6): 4-7 7) Today's Therapeutic Trends 1988; : 2-3, 1990;8(3): ) Drug Saf 1994; 10(): ) Br J Dermatol 1982; 107 Suppl. 23: ) J Steroid Biochem Mol Biol 1993 Feb; 44: ) Skin Pharmacol 1993; 6(3): ) J Am Acad Dermatol 1993 Oct: 29: ) Today's Ther Trends 1988; (4): ) Eur J Clin Pharmacol 199; 48(2): 123-1) Skin Res 1990; 32(3): ) Dermatol Venereol 1993; 2(3): ) Int J Clin Pharmacol Ther 199 Apr: 33: ) Int J Dermatol 1989 Jun: 28: ) Z Hautkr 1991; 66(9): 78-7 ) Br J Dermatol 199 Jan: 132: ) Schering-Plough Corporation Limited. data on file, November ) Proceedings of the th Annual Meeting of the American Academy of Dermatology: 1997 Mar 21-26:San Francisco 23) Poster presentation in the 19th World Congress of Dermatology, Sydney, Australia, Jun 1-, ) Curr Ther Res 1990 Jul; 48: ) Am J Clin Dermatol 02; 3 (1): 47-8

레이아웃 1

레이아웃 1 대한위장관기질종양연구회 01 GIST 06 02 11 03 Imatinib 14 04 05 06 07 Sunitinib 32 40 44 48 GIST 6 01 7 GIST Guide book GIST 8 01 9 GIST Guide book GIST (CT) MRI FDG-PET 10 02 11 GIST Guide book 12 02 (Imatinib)